Cargando…
In-vitro Activity of Avermectins against Mycobacterium ulcerans
Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance...
Autores principales: | Omansen, Till F., Porter, Jessica L., Johnson, Paul D. R., van der Werf, Tjip S., Stienstra, Ymkje, Stinear, Timothy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351077/ https://www.ncbi.nlm.nih.gov/pubmed/25742173 http://dx.doi.org/10.1371/journal.pntd.0003549 |
Ejemplares similares
-
In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera
por: Pidot, Sacha J., et al.
Publicado: (2021) -
Histopathologic Features of Mycobacterium ulcerans Infection
por: Guarner, Jeannette, et al.
Publicado: (2003) -
Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer
por: Wallace, John R., et al.
Publicado: (2017) -
Mycobacterium ulcerans not detected by PCR on human skin in Buruli ulcer endemic areas of south eastern Australia
por: Velink, Anita, et al.
Publicado: (2023) -
Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin
por: de Zeeuw, Janine, et al.
Publicado: (2014)